Integrated analysis of long non-coding RNAs in human gastric cancer: An in silico study

Weiwei Han1*, Zhenyu Zhang1*, Bangshun He2, Yijun Xu1, Jun Zhang1, Weijun Cao1*

1 Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, 2 General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China

☯ These authors contributed equally to this work.

* cwjonline@sina.cn

Abstract

Accumulating evidence highlights the important role of long non-coding RNAs (lncRNAs) in a large number of biological processes. However, the knowledge of genome scale expression of lncRNAs and their potential biological function in gastric cancer is still lacking. Using RNA-seq data from 420 gastric cancer patients in The Cancer Genome Atlas (TCGA), we identified 1,294 lncRNAs differentially expressed in gastric cancer compared with adjacent normal tissues. We also found 247 lncRNAs differentially expressed between intestinal subtype and diffuse subtype. Survival analysis revealed 33 lncRNAs independently associated with patient overall survival, of which 6 lncRNAs were validated in the internal validation set. There were 181 differentially expressed lncRNAs located in the recurrent somatic copy number alterations (SCNAs) regions and their correlations between copy number and RNA expression level were also analyzed. In addition, we inferred the function of lncRNAs by construction of a co-expression network for mRNAs and lncRNAs. Together, this study presented an integrative analysis of lncRNAs in gastric cancer and provided a valuable resource for further functional research of lncRNAs in gastric cancer.

Introduction

Gastric cancer is the fourth most common cancer and the second leading cause of cancer-related death worldwide [1]. Despite advances in treatment and understanding of the molecular basis of the disease, treatment outcome for gastric cancer still remains undesirable [2]. Long non-coding RNAs (lncRNAs) are a large class of non-protein-coding transcripts that are with more than 200 nucleotide in length. Although without apparent protein coding potential, lncRNAs play critical regulatory roles in a large number of biological processes such as chromatin remodeling, transcription, post-transcriptional processing and intracellular trafficking [3, 4]. It was also reported that IncRNAs played a role in carcinogenesis and could be diagnostic or prognostic biomarkers for gastric cancer. For example, GAPLINC was firstly identified in gastric cancer and its upregulation was associated with shorter survival of gastric cancer patients [5]. Another lncRNA, GClnc1, was up-regulated and associated with tumorigenesis, tumor size, metastasis, and poor prognosis in gastric cancer. Mechanistically, GClnc1
acted as a modular scaffold of WDR5 and KAT2A complexes and specified the histone modification pattern on the target genes, including SOD2 [6]. However, the knowledge of genome scale expression of lncRNAs and their potential biological function in gastric cancer is still lacking.

In the present study, we profiled the global expression patterns and dysregulation of lncRNAs in gastric cancer utilizing RNA-seq and clinical data from 420 gastric cancer patients in The Cancer Genome Atlas (TCGA). We then identified the lncRNAs associated with subtype and prognosis. We also investigate the global relationship between copy number and lncRNA expression. Finally, we inferred the function of lncRNAs with co-expression network analysis.

Methods

The Cancer Genome Atlas (TCGA) data

We downloaded RNA-seq data (RNA-seq V2, fastq files) for 420 gastric cancers and 36 adjacent normal tissues from TCGA Data Portal (https://tcga-data.nci.nih.gov/tcga/) and the Cancer Genomics Hub (CGHub, https://cghub.ucsc.edu/). Their related clinical data were obtained on 8 March 2016.

RNA-seq data processing

LncRNA catalogue was retrieved from GENCODE v19 [7]. The fastq files were aligned to the human reference genome (Ensembl Homo sapiens GRCh37/hg19) using Subread [8] allowing only unique mapping. Using featureCounts [9], the aligned reads were counted on gene-level based on the gene annotation from Ensembl 75 [10] (GENCODE v19).

Differential expression analysis

Read count tables were imported into the edgeR package [11] and only genes with read count > 0 in at least 75% of the samples were kept for downstream analysis. Then the data were normalized and log-counts per million (log-cpm) were calculated using the voom function of the limma package [12]. The pipeline of the empirical Bayes model implemented by limma was used to identify the differentially expressed genes between two different groups (gastric cancer vs. adjacent normal tissue, diffuse subtype vs. intestinal subtype). Benjamini and Hochberg method was used for adjusting for multiple testing [13]. Genes with adjusted p-values below 0.05 and absolute fold change > 2 were considered differentially expressed.

Additional independent dataset

Additional independent dataset from Korea [14] was downloaded from NCBI Sequence Read Archive (accession number SRP014574). The dataset contained 32 RNA-seq data of gastric cancer and adjacent normal tissue from 16 patients in Korea. Each sample was paired-end sequenced with the Illumina Genome Analyzer II or with the Illumina HiSeq 2000 using HiSeq Sequencing kits. Detailed information about the patients and samples were referenced from the publication by Yoon [14].

LncRNAs associated with prognosis

Patients with overall survival information available were randomly divided into a training set (n = 259, 66.8%) and a validation set (n = 129, 33.2%). In the training set, univariate Cox proportional hazards regression analysis was employed to explore the associations of different covariates, including lncRNA expression (continuous data), gender, age (cutoff point: median
value), grade (1 + 2 vs. 3), histological type (intestinal subtype vs. diffuse subtype), AJCC stage (stage III + IV vs. stage I + II), with patient overall survival. In the case of no death, the event time was censored at the date of last contact. Furthermore, multivariate Cox proportional hazards regression analysis was performed by combining the potential prognostic factors (with p values < 0.01 in the univariate Cox regression analysis). \( P < 0.05 \) was considered statistically significant in the multivariate Cox regression analysis. Then, lncRNAs associated with overall survival were assessed in the validation set. The survival analysis was conducted using the survival package [15].

**LncRNAs in regions of focal copy-number alteration**

Copy number segmentation data (level 3) of the Affymetrix SNP 6.0 platform were downloaded from TCGA. GISTIC2.0 [16] was used to identify genomic regions that were focally amplified or deleted. Aberrant regions were considered significant if the assigned FDR \( q \)-value was less than 0.25. The lncRNAs within these regions were identified using BEDTools [17]. The CNTools package [18] was used to process segmentation data and format the data into a gene-level matrix based on corresponding genomic location of lncRNAs. The correlation between copy number values and the corresponding gene expression levels was estimated using R (Pearson correlation).

**Co-expression network analysis**

Voom-transformed read counts of differentially expressed mRNAs and lncRNAs in gastric cancer were used as input to construct signed co-expression networks using the WGCNA package [19] in R. The adjacency matrix was calculated based on pair-wise Pearson correlation coefficients for a signed network. A value of \( \beta = 7 \) was chosen as soft-threshold power on the criterion of scale-free topology. Average linkage hierarchical clustering was performed to group genes based on Topological Overlap-based dissimilarity matrix. Modules were identified by using a dynamic tree-cutting algorithm with a minimum module size of 30 genes.

**Gene ontology and pathway enrichment analysis**

For the protein-coding genes in each modules, the DAVID bioinformatics database [20] was used to look for enrichment of genes associated with GO biological process terms and KEGG pathways.

**Results**

**Differentially expressed lncRNAs in gastric cancer**

To systematically identify lncRNAs related to gastric cancer, RNA-seq data of 420 gastric cancers and 36 adjacent normal tissues were retrieved from TCGA. After filtering of lowly expressed transcripts, 6,488 lncRNAs were kept for downstream analysis. By the criteria of adjusted \( p \)-value < 0.05 and absolute fold change > 2, we identified 1,294 lncRNAs differentially expressed in gastric cancer compared with adjacent normal tissues, among which 846 were up-regulated and 448 were down-regulated (Fig 1A and S1 Table). Unsupervised hierarchical cluster analysis revealed two separate clusters between gastric cancer and normal tissues (Fig 1C). We then analyzed the differentially expressed lncRNAs based on their categorizations. The results were indicated in Fig 1B. Antisense transcripts accounted for 44.4%, followed by lincRNAs (43.3%). The remaining non-coding transcript types were sense_intronic transcripts (6.0%), processed_transcripts (4.6%) and sense_overlapping transcripts (1.7%).
Validation of differentially expressed lncRNAs in additional independent dataset

To provide additional validation of differentially expressed lncRNAs in gastric cancer, we analyzed an independent dataset from Korea [14], which contained RNA-seq data of 16 paired gastric cancers and adjacent normal tissues. The data were processed using the same method as the TCGA dataset. We identified 342 differentially expressed lncRNAs, among which 171 were up-regulated and 171 were down-regulated (S2 Table). The overlap analysis of differentially expressed lncRNAs showed that 196 were overlapped between the Korea dataset and the TCGA dataset and only one gene was in different direction (Fig 2A). Unsupervised hierarchical cluster analysis with overlapped lncRNAs was showed as Fig 2B. Additionally, the distribution of expression differentials between two datasets was significantly concordant (Fig 2C).

LncRNAs associated with subtype

Gastric cancer is a heterogeneous disease comprised of two major histological subtypes, intestinal subtype and diffuse subtype [21]. Therefore, we compared lncRNA expression between these two subtypes. We found 192 lncRNAs were up-regulated and 55 were down-regulated in diffuse subtypes compared with intestinal subtypes (Fig 3A and S3 Table). Of the 247 lncRNAs that differentially expressed between two subtypes, 154 lncRNAs were differentially expressed between gastric cancer and adjacent normal tissue. Fig 3B and 3C showed the expression levels of two examples, PGM5-AS1 and UCA1.

LncRNAs associated with prognosis

To identify lncRNAs associated with clinical outcome in gastric cancer, patients were divided into a training set and a validation set and survival analyses were performed (Fig 4). In the training set, the univariate Cox regression analysis indicated that AJCC stage ($p = 0.0027$) and 102 lncRNAs were significantly associated with the overall survival of gastric cancer patients.
The multivariate Cox regression analysis demonstrated that AJCC stage ($p = 0.0016$) and 33 lncRNAs were independent prognostic factors (Table 1). We then tested whether these 33 lncRNAs were associated with overall survival in the validation set. 6 lncRNAs (shown in bold type in Table 1) were validated to be associated with overall survival in the validation set in univariate Cox regression analysis with $p$ value $< 0.05$.

LncRNAs in regions of somatic copy number alterations

To characterize the focal somatic copy number alterations (SCNAs) that harbor differentially expressed lncRNAs in gastric cancer, GISTIC2.0 [16] was used to identify genomic regions that were focally amplified or deleted. Then the lncRNA-containing loci were mapped to these focal alteration regions. We found 181 differentially expressed lncRNAs located in the recurrent SCNA regions (Fig 5A and S4 Table).

To estimate the contribution of SCNAs to lncRNA dysregulation in gastric cancer, we analyzed the correlation between copy number and RNA expression level for differentially expressed lncRNAs (Fig 5B). 32.42% of the lncRNAs were shown positive correlations.
(R > 0.2) between their copy numbers and RNA expression levels. For example, PVT1 and KB-1208A12.3 had a pattern of increased expression driven by copy number amplification (Fig 5C and 5D).

Co-expression network analysis

To illustrate the function of lncRNAs, we constructed a co-expression network for both mRNAs and lncRNAs that were identified as differentially expressed in gastric cancer. Using WGCNA [19], we clustered highly co-expressed genes into 6 co-expression modules (Fig 6A and S5 Table). The module size ranged from 96 to 2,951 genes. The percentage of lncRNAs in each module ranged from 13.54% (red module) to 78.92% (brown module) (Fig 6B). The turquoise module had both the highest number of genes and of lncRNAs (2,951 genes of which 629 lncRNAs).

KEGG pathway analyses and Gene ontology (GO) enrichment analyses were performed on each single module (S6 Table). Notably, pathway analysis showed that genes in green module were highly enriched in the activated pathways such as ECM-receptor interaction, focal adhesion and TGF-β signaling pathway (Fig 6C). Genes in the blue module were significantly enriched in cell cycles, p53 signaling pathway and DNA replication (Fig 6D).

Discussion

Here, we comprehensively analyzed the expression patterns of lncRNAs in gastric cancer using RNA-seq data from TCGA. We identified more than 1,000 lncRNAs differentially expressed in gastric cancer. As expected, we validated some known gastric cancer related lncRNAs, such as HOTAIR [29], PVT1 [30], GAPLNC [5], et al, which giving us confidence in our methodology. Also, we identified a large number of lncRNAs that had not been previously reported in gastric cancer. To functionally characterize these lncRNAs may substantially expand our understanding of the molecular mechanisms involved in gastric cancer pathogenesis.

We compared lncRNA expression between two major subtypes of gastric cancer, intestinal subtype and diffuse subtype. It was reported that there are underlying biologic and genomic distinctions between these two subtypes [31, 32]. Our study identified hundreds of lncRNAs showing significant subtype-specific expression patterns, which may have an important function in individual subtypes.
To identify lncRNAs with potential biological function, we analyzed the correlation between the expression levels of lncRNAs and patient overall survival using univariate and multivariate Cox regression analyses. In the training set, we identified 33 prognosis-associated lncRNAs in gastric cancer. Some of them were reported to be associated with malignancies. 6 lncRNAs were validated to be associated with overall survival in the internal validation set. However, the prognostic significance of these lncRNAs needs further investigation in an independent patient cohort. Our analysis missed some lncRNAs that have reported to be associated with overall survival of gastric cancer patients, such as GAS5 [33] and HOTAIR [34]. We think it was due to the different distributions of the patient populations in terms of age, gender, histological subtype, stage, etc.

Table 1. The list of lncRNAs independently associated with overall survival of gastric cancer.

| GeneID         | GeneName     | GeneBiotype   | HR   | P.Value   | Associated Malignancies               |
|----------------|--------------|---------------|------|-----------|---------------------------------------|
| ENSG00000223477| LINC00842    | lincRNA       | 3.0811 | 4.60E-04  |                                        |
| ENSG00000248664| CTC-498J12.3 | antisense     | 3.8   | 6.20E-04  |                                        |
| ENSG00000257877| RP3-462E2.3  | lincRNA       | 0.272 | 1.00E-03  | lung adenocarcinoma [22]               |
| ENSG00000228623| ZNF803       | lincRNA       | 2.2771 | 1.41E-03  |                                        |
| ENSG00000259005| RP3-449M8.6  | lincRNA       | 4.5295 | 1.97E-03  | papillary thyroid cancer [23]         |
| ENSG00000205562| RP11-497E19.1| lincRNA       | 2.6712 | 2.01E-03  |                                        |
| ENSG00000249650| RP11-310P5.1 | antisense     | 2.4037 | 2.10E-03  |                                        |
| ENSG00000265148| BZRAP1-AS1   | antisense     | 0.1808 | 2.99E-03  | nasopharyngeal carcinoma [24]         |
| ENSG00000254985| RSF1-IT2     | sense_intronic| 0.3269 | 4.47E-03  |                                        |
| ENSG00000229431| RP1-92014.6  | antisense     | 0.1069 | 6.25E-03  |                                        |
| ENSG00000232593| LINC0115     | lincRNA       | 0.069 | 6.33E-03  |                                        |
| ENSG000000256268| RP11-221N13.3| lincRNA       | 0.4815 | 8.14E-03  | oral cancer [25]                      |
| ENSG00000227857| RP4-533D7.5  | antisense     | 0.4507 | 8.32E-03  |                                        |
| ENSG00000251161| RP11-540O11.1| lincRNA       | 0.3641 | 1.17E-02  |                                        |
| ENSG00000267583| RP11-322E11.5| lincRNA       | 0.4109 | 1.18E-02  |                                        |
| ENSG00000235298| RP11-575L7.8 | antisense     | 3.4252 | 1.19E-02  |                                        |
| ENSG00000230107| CTA-126B4.7  | lincRNA       | 0.4419 | 1.29E-02  |                                        |
| ENSG00000203441| LINC0049     | antisense     | 0.2775 | 1.74E-02  |                                        |
| ENSG00000272109| CTD-226A17.3 | antisense     | 2.4311 | 1.77E-02  |                                        |
| ENSG00000223396| RPS1P7       | lincRNA       | 4.4906 | 1.88E-02  |                                        |
| ENSG00000235052| RP1-1505O.3  | lincRNA       | 1.8873 | 1.98E-02  | malignant mesothelioma [26]           |
| ENSG00000242147| RP13-463N16.6| lincRNA       | 1.7058 | 2.04E-02  |                                        |
| ENSG00000272707| RP11-534C12.1| lincRNA       | 0.3848 | 2.16E-02  |                                        |
| ENSG00000157152| SYN2         | processed_transcript | 1.811 | 2.33E-02  |                                        |
| ENSG00000267493| CIRBP-AS1    | antisense     | 5.2374 | 2.48E-02  | lung cancer [27]                      |
| ENSG00000227914| RP11-130C19.3| antisense     | 0.5584 | 3.53E-02  |                                        |
| ENSG00000270605| RP5-1092A3.4 | antisense     | 2.8997 | 3.65E-02  |                                        |
| ENSG00000232710| RP4-669P10.16| sense_intronic| 2.3053 | 3.87E-02  |                                        |
| ENSG00000267649| CTD-2587H24.10| lincRNA      | 0.4847 | 4.49E-02  |                                        |
| ENSG00000229656| RP11-462L8.1 | lincRNA       | 2.1174 | 4.70E-02  |                                        |
| ENSG00000271816| RP11-574K11.28| processed_transcript | 0.3661 | 4.74E-02  |                                        |
| ENSG00000228214| LINC00693    | antisense     | 0.5436 | 4.92E-02  | pancreatic ductal adenocarcinoma [28]|
| ENSG00000224066| RP4-622L5.7  | antisense     | 0.3485 | 4.99E-02  |                                        |

HR: hazard ratio. 
Bold type indicates lncRNAs validated to be associated with overall survival in the validation set.

https://doi.org/10.1371/journal.pone.0183517.t001
It has been suggested that cancer driver genes are often located in the SCNAs [35]. Previous studies have identified lncRNAs as drivers such as GAPLINC [5] and FAL1 [36]. Here, we identified 181 differentially expressed lncRNAs located in the recurrent SCNA regions. Furthermore, we identify lncRNAs which were shown positive correlations between their RNA expression levels and their gene copy numbers. For example, we found PVT1 had a pattern of increased expression driven by copy number amplification, which has been validated in a previous study [37]. We anticipated further function analysis of the lncRNAs associated with SCNAs will help to find driver lncRNAs in gastric cancer.

To illustrate the function of lncRNAs, we constructed a co-expression network for mRNAs and lncRNAs. Pathway analysis revealed genes in green module were enriched in ECM-receptor interaction, focal adhesion and TGF-β signaling pathway. It is reported these pathways played critical roles in cancer invasion and metastasis [38, 39]. So lncRNAs in this module may be involved in invasion and metastasis of gastric cancer. Interestingly, RP11-838N2.4 (also known as GAPLINC [5]) and LINC00152 [40], two lncRNAs in green module, were both reported to be associated with invasion of gastric cancer. Genes in the blue module were significantly enriched in cell cycles, p53 signaling pathway and DNA replication. It is well known that p53 signaling pathway plays the central role in maintenance of genomic stability by acting through cell-cycle arrest, senescence, and apoptosis [39, 41]. Of note, two of most well-known oncogenic lncRNAs HOTAIR [29] and PVT1 [30] were in this module. So we inferred that lncRNAs in the blue module may play important roles in gastric cancer.

Taken together, we presented an integrative analysis of lncRNAs in gastric cancer. We identified a panel of dysregulated lncRNAs that may be potential drivers and diagnostic, therapeutic
biomarkers of gastric cancer, although targeted validation of these lncRNAs is still needed. This study provided a valuable resource for further functional research of lncRNAs in gastric cancer.

Supporting information

S1 Table. Differentially expressed lncRNAs in gastric cancer.
(XLSX)

S2 Table. Differentially expressed lncRNAs of Korea dataset.
(XLSX)

S3 Table. Differentially expressed lncRNAs between intestinal subtype and diffuse subtype.
(XLSX)

S4 Table. Differentially expressed lncRNAs located in the recurrent SCNA regions.
(XLSX)

S5 Table. Co-expression network analysis using WGCNA.
(XLSX)

S6 Table. KEGG pathway analyses and GO enrichment analyses of each single module.
(XLSX)

Acknowledgments

We are grateful for all the contributions that supported this study. This study was supported by grants from Nanjing Medical University Science and Technique Development Foundation.
Project (2014N)MUZD033). Our gratitude also goes to The Cancer Genome Atlas project for generating, curating and providing high quality biological and clinical data about gastric cancer.

**Author Contributions**

**Conceptualization:** Weiwei Han, Zhenyu Zhang, Weijun Cao.

**Data curation:** Weiwei Han, Zhenyu Zhang, Bangshun He, Yijun Xu, Jun Zhang, Weijun Cao.

**Formal analysis:** Weiwei Han, Zhenyu Zhang, Bangshun He, Yijun Xu, Jun Zhang, Weijun Cao.

**Funding acquisition:** Weiwei Han, Zhenyu Zhang.

**Methodology:** Weiwei Han, Zhenyu Zhang, Bangshun He, Yijun Xu, Jun Zhang, Weijun Cao.

**Software:** Weiwei Han, Zhenyu Zhang, Weijun Cao.

**Writing – original draft:** Weiwei Han, Zhenyu Zhang.

**Writing – review & editing:** Weijun Cao.

**References**

1. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends—An Update. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2016; 25(1):16–27. https://doi.org/10.1158/1055-9965.EPI-15-0576 PMID: 26667886.

2. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016; 388 (10060):2654–64. https://doi.org/10.1016/S0140-6736(16)30354-3 PMID: 27156933.

3. Schmitt AM, Chang HY. Long Noncoding RNAs in Cancer Pathways. Cancer cell. 2016; 29(4):452–63. https://doi.org/10.1016/j.ccell.2016.03.010 PMID: 27070700; PubMed Central PMCID: PMC4831138.

4. Guttman M, Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature. 2012; 482 (7385):339–46. https://doi.org/10.1038/nature10887 PMID: 22337053; PubMed Central PMCID: PMC4197003.

5. Hu Y, Wang J, Qian J, Kong X, Tang J, Wang Y, et al. Long noncoding RNA GAPLIN C regulates CD44-dependent cell invasiveness and associates with poor prognosis of gastric cancer. Cancer research. 2014; 74(23):6890–902. https://doi.org/10.1158/0008-5472.CAN-14-0686 PMID: 25277524.

6. Sun TT, He J, Liang Q, Ren LL, Yan TT, Yu TC, et al. LncRNA GClnc1 Promotes Gastric Carcinogenesis and May Act as a Modular Scaffold of WDR5 and KAT2A Complexes to Specify the Histone Modification Pattern. Cancer discovery. 2016; 6(7):784–801. https://doi.org/10.1158/2159-8290.CD-15-0921 PMID: 27147598.

7. Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, et al. GENCODE: the reference human genome annotation for The ENCODE Project. Genome research. 2012; 22(9):1760–74. https://doi.org/10.1101/gr.135350.111 PMID: 22959987; PubMed Central PMCID: PMC3431482.

8. Liao Y, Smyth GK, Shi W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic acids research. 2013; 41(10):e108. https://doi.org/10.1093/nar/gkt214 PMID: 23558742; PubMed Central PMCID: PMC3664803.

9. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014; 30(7):923–30. https://doi.org/10.1093/bioinformatics/btu565 PMID: 24227677.

10. Cunningham F, Amode MR, Barrell D, Beal K, Billis K, Brent S, et al. Ensembl 2015. Nucleic acids research. 2015; 43(Database issue):D662–9. https://doi.org/10.1093/nar/gku1010 PMID: 25352552; PubMed Central PMCID: PMC4383879.

11. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010; 26(1):139–40. https://doi.org/10.1093/bioinformatics/btp616 PMID: 19910308; PubMed Central PMCID: PMC2796818.
12. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic acids research. 2015; 43(7):e47. https://doi.org/10.1093/nar/gkv007 PMID: 25605792; PubMed Central PMCID: PMC4402510.

13. Benjamin Y HY. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B (Stat Method). 1995; 57:289–300.

14. Yoon K, Lee S, Han TS, Moon SY, Yun SM, Kong SH, et al. Comprehensive genome- and transcriptome-wide analyses of mutations associated with microsatellite instability in Korean gastric cancers. Genome research. 2013; 23(7):1109–17. https://doi.org/10.1101/gr.145706.112 PMID: 23737375; PubMed Central PMCID: PMC3698504.

15. T T. A package for survival analysis in S. R package version 2.37–4. R. 2013; 1(1):1.

16. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome biology. 2011; 12(4):R41. https://doi.org/10.1186/gb-2011-12-4-r41 PMID: 21527027; PubMed Central PMCID: PMC3218867.

17. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010; 26(6):841–2. https://doi.org/10.1093/bioinformatics/btq033 PMID: 20110278; PubMed Central PMCID: PMC2832824.

18. Lauren P. The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Call ed Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. Acta pathologica et microbiologica Scandinavica. 1965; 64:31–49. PMID: 14320675.

21. Zhang L, Li S, Choi YL, Lee J, Gong Z, Liu X, et al. Systematic identification of cancer-related long non-coding RNAs and aberrant alternative splicing of quintuple-negative lung adenocarcinoma through RNA-Seq. Lung cancer. 2017; 109:21–7. https://doi.org/10.1016/j.lungcan.2017.04.009 PMID: 28577945.

22. Luo YH, Liang L, He RQ, Wen DY, Deng GF, Yang H, et al. RNA-sequencing investigation identifies an effective risk score generated by three novel IncRNAs for the survival of papillary thyroid cancer patients. Onco-target. 2017. https://doi.org/10.18632/oncotarget.18274 PMID: 28618399.

23. Feigin ME, Garvin T, Bailey P, Waddell N, Chang DK, Kelley DR, et al. Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nature genetics. 2017; 49(6):825–33. https://doi.org/10.1038/ng.3861 PMID: 28481342.

24. Wang X, Zhang Y, Nilsson CL, Berven FS, Andren PE, Carlsohn E, et al. Association of chromosome 19 to lung cancer genotypes and phenotypes. Cancer metastasis reviews. 2015; 34(2):217–26. https://doi.org/10.1007/s10555-015-9556-2 PMID: 25982285.

25. A package for survival analysis in S. R package version 2.37–4. R. 2013; 1(1):1.
31. Kalamohan K, Periasamy J, Bhaskar Rao D, Barnabas GD, Ponnaiyan S, Ganesan K. Transcriptome coexpression network reveals the involvement of varying stem cell features with different dysregulations in different gastric cancer subtypes. Molecular oncology. 2014; 8(7):1306–25. https://doi.org/10.1016/j.molonc.2014.04.005 PMID: 24917244.

32. McLean MH, El-Omar EM. Genetics of gastric cancer. Nature reviews Gastroenterology & hepatology. 2014; 11(11):664–74. https://doi.org/10.1038/nrgastro.2014.143 PMID: 25134511.

33. Sun M, Jin FY, Xia R, Kong R, Li JH, Xu TP, et al. Decreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell proliferation in gastric cancer. BMC cancer. 2014; 14:319. https://doi.org/10.1186/1471-2407-14-319 PMID: 24884417; PubMed Central PMCID: PMC4022532.

34. Endo H, Shiroki T, Nakagawa T, Yokoyama M, Tamai K, Yamanami H, et al. Enhanced expression of long non-coding RNA HOTAIR is associated with the development of gastric cancer. PloS one. 2013; 8(10):e77070. https://doi.org/10.1371/journal.pone.0077070 PMID: 24130837; PubMed Central PMCID: PMC3795022.

35. Zack TI, Schumacher SE, Carter SL, Chernick AD, Saksena G, Tabak B, et al. Pan-cancer patterns of somatic copy number alteration. Nature genetics. 2013; 45(10):1134–40. https://doi.org/10.1038/ng.2760 PMID: 24071852; PubMed Central PMCID: PMC3966983.

36. Hu X, Feng Y, Zhang D, Zhao SD, Hu Z, Greshock J, et al. A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. Cancer cell. 2014; 26(3):344–57. https://doi.org/10.1016/j.ccr.2014.07.009 PMID: 25203321; PubMed Central PMCID: PMC4159613.

37. Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H, et al. PVT1 dependence in cancer with MYC copy-number increase. Nature. 2014; 512(7512):82–6. https://doi.org/10.1038/nature13311 PMID: 25049044; PubMed Central PMCID: PMC4767149.

38. Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO reports. 2014; 15(12):1243–53. https://doi.org/10.15252/embr.201439246 PMID: 25381661; PubMed Central PMCID: PMC4264927.

39. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013 PMID: 21376230.

40. Zhao J, Liu Y, Zhang W, Zhou Z, Wu J, Cui P, et al. Long non-coding RNA Linc00152 is involved in cell cycle arrest, apoptosis, epithelial to mesenchymal transition, cell migration and invasion in gastric cancer. Cell cycle. 2015; 14(19):3112–23. https://doi.org/10.1080/15384101.2015.1078034 PMID: 26237576; PubMed Central PMCID: PMC4825539.

41. Stracquaddanio G, Wang X, Wallace MD, Grawenda AM, Zhang P, Hewitt J, et al. The importance of p53 pathway genetics in inherited and somatic cancer genomes. Nature reviews Cancer. 2016; 16(4):251–65. https://doi.org/10.1038/nrc.2016.15 PMID: 27009395.